Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 4/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044984 | 0.92 | RELA (0.59) | RELACA2PPARACA1 | |
| SCHEMBL14081714 | 0.89 | RELA (0.81) | RELACA2PPARACA1DNM1 | |
| SCHEMBL29098369 | 0.89 | RELA (0.81) | RELACA2PPARACA1DNM1 | |
| SCHEMBL14081731 | 0.88 | RELA (0.79) | RELACA2PPARAFAAHCA1 | |
| SCHEMBL14081732 | 0.88 | RELA (0.79) | RELACA2PPARAFAAHCA1 | |
| SCHEMBL8468160 | 0.85 | RELA (0.71) | RELACA2PPARAFAAHCA1 | |
| SCHEMBL9609767 | 0.85 | RELA (0.71) | RELACA2PPARAFAAHCA1 | |
| SCHEMBL18572502 | 0.85 | RELA (0.71) | RELACA2PPARAFAAHCA1 | |
| SCHEMBL7687766 | 0.85 | RELA (0.66) | RELACA2PPARAFAAHCA1 | |
| SCHEMBL7685651 | 0.85 | RELA (0.71) | RELACA2PPARAFAAHCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2010048340-A2 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, ALG8, ALG1 | RELA 2252/4885CA2 3594/4885PPARA 3299/4885 |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, DNPEP, ALG8 | RELA 2123/4885CA2 2937/4885PPARA 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.